Quarterly Results
BPMC Earnings Forecast
Looking ahead, BPMC remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 171.34M and an EPS of undefined.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in BPMC long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how BPMC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BPMC sees a -2.41% change in stock price 10 days leading up to the earnings, and a +0.73% change 10 days following the report. On the earnings day itself, the stock moves by +5.36%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed 5.43% on the day following the earnings release and then changed by 0.24% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of BPMC's latest earnings report for FY2025Q1?
BPMC reported its FY2025Q1 earnings on 2025-05-01, showcasing a revenue of 149.41M against an estimate of 156.89M, resulting in a -4.77% surprise. The EPS was -0.74, surpassing the expected -0.42 by -76.19% . The stock experienced a 10.89% price change on the earnings day and a 10.79% change over the next five days, reflecting market reactions to the results.
How did BPMC's stock price react after the FY2025Q1 earnings release?
Following BPMC's FY2025Q1 earnings announcement on 2025-05-01, the stock price moved by 10.89% on the day of the release. Over the subsequent five days, it saw a 10.79% change. Historically, BPMC's stock price tends to shift by an average of -2.41% in the 10 days leading up to earnings and +0.73% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for BPMC for 2025/Q2?
For 2025/Q2, analysts estimate BPMC’s annual revenue to reach 171.34M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.
How does BPMC's stock price correlate with earnings forecast revisions?
The correlation between BPMC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from BPMC's next earnings report?
Based on historical trends, BPMC's stock price typically moves by -2.41% in the 10 days before its earnings and +0.73% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 171.34M.
What is the sentiment in Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Summary?
The earnings call highlights strong financial performance with a 61% YoY growth in AYVAKIT revenues and raised guidance, indicating confidence in future growth. The company maintains a robust cash position, supporting ongoing investments. Despite no shareholder return plan, the focus on market expansion and product development is promising. The Q&A reveals optimism about growth drivers and patient engagement, although some responses were vague. Overall, the positive revenue growth, solid cash position, and raised guidance outweigh the lack of immediate shareholder returns, suggesting a positive stock price movement.
